BRD2 and neoplasm: By performing immunohistochemical staining on patients’ samples to further validated KNSTRN expression levels in the tumor and NAT of patients with TNBC and Non-TNBC (Figure 3A), we observed that KNSTRN was expressed at higher levels in both TNBC and Non-TNBC tumor tissues compared to their NAT (Figures 3B, C).